5.7. diagnostic pathway clinical practice?. ‘combined pathway’, patients positive mri undergo combined systematic targeted biopsy, patients negative mri undergo systematic biopsy, maximises detection isup grade group ≥2 cancers. however, disadvantage leading greater detection isup grade group 1 cancers referring patients clinical suspicion cancer biopsy. given growing concerns over-detection insignificant pca, development protocols patients isup grade group 2 cancers (see section 6.2.1.2.1) grade shift induced mri-targeted biopsy (see section 5.5.5) clinical relevance diagnostic strategy aimed maximising detection isup grade group ≥ 2 cancers questionable . ‘mri pathway’ patients positive mri undergo mri-targeted biopsy patients negative mri biopsied could avoid biopsy 21-49% patients pi-rads threshold ≥3 used trigger biopsy , cost missing significant cancers, especially biopsy-naïve patients highly selected populations high prevalence cspca (in mri npv decreases) . several alternative mri-directed diagnostic pathways envisaged correct limitations, example selecting patients biopsy based combination mri findings clinical data adding perilesional sampling mri-targeted biopsy. best pathway remains unclear prospective evaluations lacking. interestingly, study different mri-directed pathways compared classical combined pathway retrospective cohort 499 men. highest clinical utility risk threshold 6.25% obtained risk-based pathway patients pi-rads score 1-3 low-risk profile (psa-d<0.15 ng/ml/cc, negative dre, family history, asap isup1 cancer prior biopsy) could forgo biopsy others underwent combined systematic mri-targeted biopsy. pathway, biopsy could avoided 99 men (19%) missing isup grade group ≥ 2 cancers 6 men (1.2%) . 5.7.1. repeat biopsy negative biopsy follow-up negative systematic biopsy, incidence pca higher, risk pca death lower population average . men prior negative systematic biopsy persistent suspicion pca mri already performed. significant pca may still present men abnormal mri negative targeted biopsy . follow-up direct repeat biopsy considered dependent risk factors (e.g. psa density, pirads). contemporary series biopsies likelihood finding cspca follow-up biopsy diagnosis atypical small acinar proliferation high-grade prostatic intraepithelial neoplasia (pin) 6-8%, significantly different follow-up biopsies negative biopsy . added value biomarkers remains unclear (see sections 5.2.5.1 5.2.5.2). 5.7.2. saturation biopsy incidence pca detected saturation repeat biopsy (> 20 cores) 30–43% depends number cores sampled earlier biopsies . saturation biopsy may performed transperineal technique, detects additional 38% pca. rate urinary retention varies substantially 1.2% 10% . however, given low risk subsequent cspca negative biopsy and/or case negative mri, clinical utility saturation biopsy repeat biopsy setting remains uncertain current mri-driven diagnostic pathway schemes routinely used . 5.7.3. seminal vesicle biopsy indications sv (staging) biopsies poorly defined. psa > 15 ng/ml, odds tumour involvement 20–25% . sv staging biopsy useful decisive impact treatment, ruling radical tumour resection potential subsequent rt. added value compared mri questionable. 5.7.4. transition zone biopsy transition zone sampling baseline biopsies low detection rate limited mri detected lesions repeat template biopsies .